Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
American Journal of Hematology|March 10, 2026
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin LymphomaFuxin Han, Yadi Zhong, Chuan Tong, et al.Journal of Genetics and Genomics = Yi Chuan Xue Bao|June 6, 2026
The TNFR2<sup>M196R</sup> germline variant confers dual impact on CAR-T cell immunotherapy by enhancing T-cell survival and tumor proliferationNan Liu, Lu Han, Yuting Lu, et al.Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 19, 2025
Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapyFuxin Han, Yuting Lu, Yipeng Zhang, et al.Leukemia|July 17, 2021
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trialYajing Zhang, Yao Wang, Yang Liu, et al.Protein & Cell|March 12, 2017
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivoYanjing Song, Chuan Tong, Yao Wang, et al.Blood Advances|June 21, 2022
CD58 loss in tumor cells confers functional impairment of CAR T cellsXin Yan, Deyun Chen, Xinran Ma, et al.Science Advances|May 8, 2026
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cellsYelei Guo, Chuan Tong, Jianshu Wei, et al.Journal of Hematology & Oncology|June 12, 2019
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantationHejin Jia, Zhenguang Wang, Yao Wang, et al.Science China. Life Sciences|March 25, 2016
An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cellsYajing Zhang, Wenying Zhang, Hanren Dai, et al.Journal of Hematology & Oncology|April 5, 2020
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemiaHanren Dai, Zhiqiang Wu, Hejin Jia, et al.Pageof 4